The Christie in Manchester was the first UK cancer centre to set up a SIRT service in 2005 and it remains one of the biggest providers of selective internal radiation therapy in the country. The service started with private patients and expanded in 2009 when our audited results from this treatment led to the NHS commissioning us to provide SIRT for NHS patients within our network.

Our multidisciplinary team includes medical and radiation oncologists, interventional radiologists, nuclear medicine specialists, liver surgeons and specialist nurses. Patients being considered for SIRT should be referred to an oncologist within the SIRT team.

SIRT team

Consultant Oncologists

Dr Gregory Wilson MBChB, DRCOG, FRCP, Dip Onc

Consultant Medical Oncologist

Interests: breast cancer, colorectal cancer, targeted liver therapies, carcinoma unknown primary

Dr Greg Wilson is Lead Clinician for the SIRT programme at The Christie and treated the first patient with SIRT at The Christie in 2005. He is a member of the European Society of Medical Oncology (ESMO) and American Society of Clinical Oncology (ASCO) and has lectured extensively on the use of SIRT for the treatment of malignancy in the liver including breast and colorectal cancer. Dr Wilson has a particular interest in the management of complex secondary cancer in the liver. He is an active member of the breast and colorectal cancer disease groups at The Christie.

website: www.drgregwilson.co.uktwitter: @uk_oncologist

Professor Juan Valle MBChB, MSc, FRCP

Consultant Medical Oncologist

Interests: hepatopancreatobiliary, hepatocellular and neuroendocrine tumours

Professor Juan Valle is Lead Clinician for the Hepatobiliary and Neuroendocrine Tumour Service at The Christie. He is a member of the UK National Cancer Research Institute (NCRI) upper gastrointestinal clinical studies group, a member of the pancreatic cancer and hepatobiliary subgroups, and he chairs the neuroendocrine subgroup. Professor Valle is also a member of the following professional societies: ESMO, ASCO, UKI NETS (UK and Ireland Neuroendocrine Tumour Society) and ENETS (European Neuroendocrine Tumour Society).

Dr Saifee Mullamitha MBBS, MD, FRCP

Consultant Medical Oncologist 

Interests: colorectal cancer, targeted liver therapies, carcinoma unknown primary

Dr Saifee Mullamitha is a consultant medical oncologist with a dedicated and specific interest in the personalised management of colorectal cancer. He is a lead principal investigator and co-investigator in a number of national as well as international clinical trials. Apart from patients within the region, Dr Mullamitha has co-ordinated treatment plans such as SIRT (colorectal/breast cancer) or PTC, etc. for patients from outside Manchester. He has an interest in the management pathways, clinical trials and investigation for cancers from unknown primary. Apart from his educational portfolio Dr Mullamitha is also an examiner with the South Manchester University Hospitals.

Dr Jurjees Hasan MSc, MD, FRCP

Consultant Medical Oncologist 

Interests: colorectal cancer, targeted liver therapies, gynaecological malignancy

Dr Jurjees Hasan is a consultant medical oncologist with interests in colorectal and gynaecological malignancy. He also maintains an interest in translational research into the development of new strategies for the management of malignant bowel obstruction and liver-directed therapies for colorectal cancer. Dr Hasan is a member of the colorectal team and the lead medical oncologist for gynaecological malignancies for South Manchester.

Consultant Radiologists

Dr Jeremy Lawrance MBChB, MRCP, FRCR

Consultant Interventional Radiologist

Interests: oncological radiology, vascular interventional radiology

Dr Jeremy Lawrance is the lead interventional vascular radiologist and is a divisional medical director at The Christie. He performed the first SIRT procedure at The Christie in 2005 and performs multiple interventional vascular radiology procedures as part of the SIRT and other programmes. Dr Lawrance and his team have developed the SIRT service at The Christie into one of the leading SIRT centres in Europe. 

Dr Hans-Ulrich Laasch MRCP, FRCR, CCST

Consultant Interventional Radiologist

Interests: oncological radiology, interventional radiology

Dr Hans-Ulrich Laasch is the interventional lead for The Christie with particular interest in hepatobiliary intervention, GI stents, nutritional support and sedation. He undertook a four year fellowship in interventional gastrointestinal radiology and endoscopy and is a Fellow of the European Society of GI and Abdominal Radiology. The Radiology department at The Christie is a reference site for 6 device companies, and Dr Laasch plays an active role in education on a national and international level and is a technical advisor for the National Institute of Clinical Excellence (NICE).

Dr Damian Mullan MBChB BAO, MRCS, MCEM, FRCR, FFR (RCSI)

Consultant Interventional Radiologist

Interests: oncological radiology, vascular and GI interventional radiology

Dr Damian Mullan is a consultant interventional radiologist at The Christie. He holds fellowship by examination of both Irish and UK Royal Colleges. Dr Mullan trained in surgery and emergency medicine in Dublin, prior to commencing clinical radiology training in Liverpool, and completed a fellowship programme in interventional radiology at The Christie before his appointment as a consultant in 2010. He specialises in gastrointestinal, vascular and oncological intervention.

Dr Jon Bell BSc, MBChB (Hons), MRCS (Eng), FRCR, EBIR, PGCertMedEd, MAcadMEd

Consultant Interventional Radiologist

Interests: oncological radiology, interventional oncology including vascular and non-vascular procedures

Dr Bell is a consultant interventional radiologist at The Christie. After graduating with honours from the University of Manchester, he trained in surgery and clinical radiology. He then completed higher subspecialty training in interventional radiology in Manchester and has completed the European Board of Interventional Radiology (EBIR). Dr Bell is a member of the Faculty Board of the Royal College of Radiologists and the Safety and Quality Committee of the British Society of Interventional Radiology.